Open AccessEndostatin and ST2 are predictors of pulmonary hypertension disease course in infants
Author(s) -
Megan Griffiths,
Jun Yang,
Allen D. Everett,
Jacky M. Jennings,
Grace Freire,
Mónica Williams,
Melanie Nies,
Sharon A. McGrathMorrow,
Joseph M. Collaco
Publication year - 2020
Publication title -
journal of perinatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.912
H-Index - 94
eISSN - 1476-5543
pISSN - 0743-8346
DOI - 10.1038/s41372-020-0671-8
Subject(s) - medicine , endostatin , pulmonary hypertension , biomarker , ductus arteriosus , cardiology , heart disease , comorbidity , heart failure , disease , gastroenterology , angiogenesis , biochemistry , chemistry
Pulmonary hypertension (PH) is a common comorbidity of cardiopulmonary disease. Endostatin, an inhibitor of angiogenesis, is elevated in neonates with lung disease. ST2 is a heart failure biomarker correlated with PH in adults. We hypothesized that these biomarkers may be useful in diagnosing PH and categorizing its severity in infants.